Skip to main content

Neoadjuvant Chemo Boosts Structure Preservation Rates in Nasal, Sinus Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 18, 2024.

By Elana Gotkine HealthDay Reporter

WEDNESDAY, Sept. 18, 2024 -- Neoadjuvant platinum-based chemotherapy improves structure preservation (SP) for patients with T3, T4a, and selected T4b resectable nasal and paranasal sinus squamous cell carcinoma (NPNSCC) requiring orbital or skull base resection, according to a study presented at the annual meeting of the European Society for Medical Oncology, held from Sept. 13 to 17 in Barcelona, Spain.

Nabil F. Saba, M.D., from Winship Cancer Institute of Emory University in Atlanta, and colleagues reported the SP analysis in a study involving patients with T3, T4a, and selected T4b resectable NPNSCC. Participants were randomly allocated to receive surgery followed by postoperative radiation therapy of 60 Gy (standard arm) or the same treatment preceded by three cycles of neoadjuvant docetaxel 75 mg/m2 and cisplatin 75 mg/m2 (experimental arm). The SP rate and overall survival were the co-primary objectives.

After enrolling 29 patients, the study was closed due to slow accrual in November 2023. The researchers found that the overall SP rate was 32 percent among 22 evaluable patients, with rates of 15 and 56 percent in the standard arm and experimental arm, respectively. The overall orbit preservation rate was 55 percent, with rates of 46 and 67 percent in the standard and experimental arms, respectively. The overall skull base preservation rate was 55 percent, with rates of 38 and 78 percent, respectively, in the standard and experimental arms.

"Despite being unable to complete the planned accrual and reach a definitive answer, the study results are striking and support the use of neoadjuvant chemotherapy as an intervention that could improve the chance of organ preservation for these patients," Saba said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Childhood Cancer Survivors Have Increased Risk for CKD, Hypertension

THURSDAY, May 22, 2025 -- Childhood cancer survivors (CCS) have an increased risk for chronic kidney disease (CKD) and hypertension, according to a study published online May 19...

Testosterone Use Not Tied to Gynecological Cancers in Transmasculine Individuals

FRIDAY, May 16, 2025 -- Short-term testosterone use among transmasculine and gender diverse (TMGD) individuals is not associated with an increased risk for gynecological cancers...

Increases in Incidence Rates of Some Cancers Seen in Early-Onset Age Groups

THURSDAY, May 15, 2025 -- The incidence rates of 14 cancers have increased in early-onset age groups, with increases in older-onset age groups also occurring in most of these...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.